Xenon Pharmaceuticals Inc.
DE ˙ DB ˙ CA98420N1050
45,60 € ↑1,00 (2,24%)
2026-06-04
DEL PRIS
SecurityDE:XP0 / Xenon Pharmaceuticals Inc.
InstitutionEngineers Gate Manager LP
Latest Disclosed Ownership9,326 shares
Latest Disclosed Value $ 542,307
Engineers Gate Manager LP ownership in XP0 / Xenon Pharmaceuticals Inc.

On May 15, 2026 - Engineers Gate Manager LP filed a 13F-HR form disclosing ownership of 9,326 shares of Xenon Pharmaceuticals Inc. (DE:XP0) valued at $447,648 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 14, 2025 disclosing 0 shares of Xenon Pharmaceuticals Inc.. The current value of the position is $425,266 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F XENON PHARMACEUTICALS COM 98420N105 9,326 9,326 542 0.0068
2025-02-14 2024-12-31 13F XENON PHARMACEUTICALS COM 98420N105 0 -5,581 -100.00 0 -100.00
2024-11-14 2024-09-30 13F XENON PHARMACEUTICALS COM 98420N105 5,581 -23,712 -80.95 220 -80.82 0.0043
2024-08-14 2024-06-30 13F XENON PHARMACEUTICALS COM 98420N105 29,293 2,780 10.49 1,142 0.09 0.0258
2024-05-15 2024-03-31 13F XENON PHARMACEUTICALS COM 98420N105 26,513 26,513 1,141 0.0300
2023-05-15 2023-03-31 13F XENON PHARMACEUTICALS COM 98420N105 0 -14,383 -100.00 0 -100.00
2023-02-14 2022-12-31 13F XENON PHARMACEUTICALS COM 98420N105 14,383 4,666 48.02 567 61.54 0.0341
2022-11-14 2022-09-30 13F XENON PHARMACEUTICALS COM 98420N105 9,717 -13,030 -57.28 351 -49.28 0.0218
2022-08-15 2022-06-30 13F XENON PHARMACEUTICALS COM 98420N105 22,747 -10,058 -30.66 692 -31.01 0.0254
2022-05-16 2022-03-31 13F XENON PHARMACEUTICALS COM 98420N105 32,805 23,722 261.17 1,003 253.17 0.0393
2022-02-14 2021-12-31 13F XENON PHARMACEUTICALS COM 98420N105 9,083 -5,067 -35.81 284 31.48 0.0128
2021-11-15 2021-09-30 13F XENON PHARMACEUTICALS COM 98420N105 14,150 14,150 216 0.0123
2021-08-16 2021-06-30 13F XENON PHARMACEUTICALS COM 98420N105 0 -11,330 -100.00 0 -100.00
2021-05-17 2021-03-31 13F XENON PHARMACEUTICALS COM 98420N105 11,330 11,330 203 0.0101
2020-08-17 2020-06-30 13F XENON PHARMACEUTICALS COM 98420N105 0 -16,286 -100.00 0 -100.00
2020-05-15 2020-03-31 13F XENON PHARMACEUTICALS COM 98420N105 16,286 16,286 185 0.0133
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.